A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic
Mayo Clinic
Bristol-Myers Squibb
National Institutes of Health Clinical Center (CC)
SymBio Pharmaceuticals
City of Hope Medical Center
Mayo Clinic
Case Comprehensive Cancer Center
City of Hope Medical Center
UNC Lineberger Comprehensive Cancer Center
Barbara Ann Karmanos Cancer Institute
UNC Lineberger Comprehensive Cancer Center
City of Hope Medical Center
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Memorial Sloan Kettering Cancer Center
Washington University School of Medicine
Wake Forest University Health Sciences
Stanford University
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
University of Nebraska
University of Nebraska
Eastern Cooperative Oncology Group
Massachusetts General Hospital
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Rutgers, The State University of New Jersey
Northwestern University
Northwestern University
Roswell Park Cancer Institute
Universität des Saarlandes
Fred Hutchinson Cancer Center
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)
Mayo Clinic
M.D. Anderson Cancer Center
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Case Comprehensive Cancer Center
Mayo Clinic
Canadian Cancer Trials Group
Barbara Ann Karmanos Cancer Institute
Mayo Clinic
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Acrotech Biopharma Inc.
Fred Hutchinson Cancer Center
University of Wisconsin, Madison
National Cancer Institute (NCI)